Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Introgen Anticipates Completion Of Advexin Rolling BLA Submission In 2007

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Biologic may have synergistic effects with ImClone’s Erbitux and Genentech’s Avastin, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients

BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.

Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients

BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.

Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia

Firm expects to ship product within 2-3 weeks, Cephalon tells “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Recent And Upcoming FDA Advisory Committee Meetings

EU CHMP Opinions and MAA Updates

See All
UsernamePublicRestriction

Register

PS063614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By